Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom
Published on 2025-05-12 04:42:08 -
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
The article from NBC New York discusses how several pharmaceutical companies are making new investments in the U.S. amid looming tariffs on Chinese pharmaceuticals proposed by former President Donald Trump. Companies like Eli Lilly, Merck, and Pfizer are expanding their U.S. operations, with Eli Lilly investing $450 million in a new manufacturing facility in North Carolina, Merck planning a $1 billion expansion in Virginia, and Pfizer announcing a $1.5 billion investment in North Carolina. These investments are seen as a strategic move to mitigate the impact of potential tariffs, which could increase costs for drugs imported from China. The article highlights that these expansions not only aim to bolster domestic production but also to create jobs and enhance the companies' capabilities in the U.S. market.
Read the Full NBC New York Article at: [ https://www.nbcnewyork.com/news/business/money-report/healthy-returns-here-are-the-drugmakers-with-new-u-s-investments-as-trumps-pharma-tariffs-loom/6245295/ ]
Stocks & Investing
